Blinatumomab prolongs survival after MRD-negative...

Blinatumomab prolongs survival after MRD-negative…

7 August, 2024 doctor 0 Comments 1 category

medicine

Tuesday, August 6, 2024

Rochester/Minnesota Additional treatment with the BITE antibody blinatumomab can improve the results of consolidation chemotherapy in patients with BCR::ABL1-negative B-precursor ALL who had no minimal residual disease (MRD) after previous induction therapy. An American phase 3 study, the results of which were published in the New England Journal of Medicine (NEJM 2024; DOI: 10.1056/NEJMoa2312948),…

#Blinatumomab #prolongs #survival #MRDnegative..

Tags:
Category: Medical Encyclopedia

Leave a Reply

Related Posts